ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This research study will test the safety of the investigational drug, ZD6474, in combination
with 2 other drugs that are standard in the treatment of colon and rectal cancer (cetuximab
and irinotecan). ZD6474 blocks the action of two substances in the body: vascular endothelial
growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR). VEGFR stimulates
the formation of new blood vessels. When cancer cells produce VEGFR, new blood vessels are
made that provide blood to the cancer cells. The blood carries nutrients and oxygen, allowing
the cancer cells to live and grow. EGFR controls how quickly cells grow and multiply. Both of
these substances are found on normal cells, but they are found in much higher levels on
cancer cells.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
AstraZeneca Beth Israel Deaconess Medical Center Massachusetts General Hospital